DSG3-CAART

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDSG3-CAART
Drug Alias NameDSG3 CAAR T-cell therapy (University of Pennsylvania/Cabaletta)Dsg3 CAAR-T cells (University of Pennsylvania)anti-DSG-3 CAR T-cell therapy (University of Pennsylvania/Cabaletta/Oxford Biomedica)DSG3-CAART
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionDesmoglein-3 modulators
TargetsDesmoglein-3
Therapy Area/IndicationsPemphigus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesOxford Biomedica PLCUniversity Of PennsylvaniaCabaletta Bio Inc
Inactive CompaniesN/A
Active IndicationsPemphigus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A